Additional file 10 of Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Additional file 10. Figure showing survival analyses of cyclin E1 and E2 in fulvestrant-treated metastatic breast cancer patients. Kaplan-Meier plot for overall survival (OS) in cyclin E2 low versus high expression in ER+ metastatic breast cancer patients treated with fulvestrant in the advanced setting (A) and for progression-free (PFS) (B) and overall (C) survival in cyclin E1 low versus high expression in the same patient material. P-value represents log-rank test for OS and PFS, respectively, between patients with high and low levels of cyclin E1 or E2 expression.